Treatment of Retinopathy of Prematurity with topical ketorolac tromethamine: a preliminary study

BMC Pediatrics

Table 1 Characteristics of newborns treated with ketorolac and historic controls.

	Historic controls	Ketorolac	p**
	Year 1999 – 2000	Year 2001–2002
	N = 35†	N = 43†
	n(%)	n(%)
Dead before discharge*	18 (34.0)	16 (27.1)	0.54
Birthweight (g)			0.28
<= 750	4 (11.4)	8 (18.6)
751–1000	13 (37.1)	9 (20.9)
1001–1250	18 (51.4)	26 (60.59
Apgar Score < 6 at 5 minutes	10 (28.6)	11 (25.5)	0.80
Oxygen (days)			0.01
0–10	9 (25.7)	21 (48.8)
11–27	10 (28.6)	15 (34.9)
>= 28	16 (45.7)	7 (16.3)
Sepsis	16 (45.7)	24 (55.8)	0.50
Peri–intraventricular hemorrhage > grade III	8 (22.9)	6 (14.0)	0.38
Necrotizing Enterocolitis >= II degree	5 (14.3)	9 (20.9)	0.56

† Excludes newborns that died before discharge. * N = 53 in historic controls group and N = 59 in ketorolac group, that includes all eligible live newborn during the study period. ** P-value Fisher exact test.

ISSN: 1471-2431